These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1680448

  • 21. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W, Matuszkiewicz-Rowińska J, Tomik Z, Andrzejewski A, Rokicka M, Paszkowska M, Drygieniec D, Bobilewicz D, Zawadzka M, Abbas-Fatah A.
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [Abstract] [Full Text] [Related]

  • 22. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
    Grzeszczak W, Sulowicz W, Rutkowski B, de Vecchi AF, Scanziani R, Durand PY, Bajo A, Vargemezis V, European Collaborative Group.
    Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
    [Abstract] [Full Text] [Related]

  • 23. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B, Polito-Bouloux C, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.
    Nephrologie; 1990 May; 11(1):5-10. PubMed ID: 2374643
    [Abstract] [Full Text] [Related]

  • 24. Erythropoietin response and route of administration.
    Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK.
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [Abstract] [Full Text] [Related]

  • 25. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
    Nesić V, Ostrić V, Kovacević Z, Dimković N, Curić S, Lazarević M, Ratković M, Bogdanović J, Jelacić R.
    Med Pregl; 2005 May; 58(5-6):279-85. PubMed ID: 16526235
    [Abstract] [Full Text] [Related]

  • 26. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC, Lai YH, Tsai ZY, Chien LJ, Tsai JH.
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [Abstract] [Full Text] [Related]

  • 27. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
    Lubrich-Birkner I, Schollmeyer P, Steinhauer HB.
    Adv Perit Dial; 1990 Mar; 6():302-7. PubMed ID: 1982833
    [Abstract] [Full Text] [Related]

  • 28. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B.
    Ren Fail; 2005 Mar; 27(4):367-72. PubMed ID: 16060121
    [Abstract] [Full Text] [Related]

  • 29. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y, Jirajan B, Krairithichai U, Jantavanich N.
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [Abstract] [Full Text] [Related]

  • 30. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity.
    Bajo MA, Selgas R, Miranda B, Fernandez-Zamorano A, Borrego F, Romero JR, Caparros G, Riñon C, Sanchez Sicilia L.
    Adv Perit Dial; 1991 Sep; 7():296-300. PubMed ID: 1680450
    [Abstract] [Full Text] [Related]

  • 31. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
    Pljesa S.
    Med Pregl; 2007 Sep; 60(3-4):123-7. PubMed ID: 17853722
    [Abstract] [Full Text] [Related]

  • 32. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.
    Nakamoto H, Kanno Y, Okada H, Suzuki H.
    Adv Perit Dial; 2004 Sep; 20():111-6. PubMed ID: 15384808
    [Abstract] [Full Text] [Related]

  • 33. [Maintenance therapy on the anemia in continuous ambulatory peritoneal dialysis (CAPD) patients using subcutaneous administration of recombinant human erythropoietin fortnightly--a multicenter trial].
    Kubota M, Kawaguchi Y, Nomoto Y, Tsuchida H, Nihei H, Kubo K, Omori Y, Babazono T, Ogura Y, Hara S.
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1081-90. PubMed ID: 8230819
    [Abstract] [Full Text] [Related]

  • 34. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 36. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
    Ahsan N.
    Adv Perit Dial; 2000 Apr; 16():80-4. PubMed ID: 11045266
    [Abstract] [Full Text] [Related]

  • 37. Treatment of the anemia with human recombinant erythropoietin in CAPD patients.
    Miranda B, Selgas R, Riñon C, Fernandez-Zamorano A, Borrego F, Ortuño F, Lopez-Revuelta K, Torre A, Sanchez Sicilia L.
    Adv Perit Dial; 1990 Apr; 6():296-301. PubMed ID: 1982831
    [Abstract] [Full Text] [Related]

  • 38. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y.
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [Abstract] [Full Text] [Related]

  • 39. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
    Messa P, Nicolini MA, Cesana B, Brezzi B, Zattera T, Magnasco A, Moroni G, Campise M.
    Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
    [Abstract] [Full Text] [Related]

  • 40. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.